Evidence map›Paper›PMID 38772950›Full record

ArticleFunctional & integrative genomics2024

Whole blood transcriptome signature predicts severe forms of COVID-19: Results from the COVIDeF cohort study.

Roberta Armignacco, Nicolas Carlier, Anne Jouinot, Maria Francesca Birtolo, Daniel de Murat, Florence Tubach, Pierre Hausfater, Tabassome Simon, Guy Gorochov, Valérie Pourcher and 6 more

Abstract read
In one paragraph

Article in Functional & integrative genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Roberta ArmignaccoUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France. roby.army@hotmail.it.
Nicolas CarlierService de Pneumologie, AP-HP, Hôpital Cochin, 75014, Paris, France.
Anne JouinotUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France.
Maria Francesca BirtoloUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France.
Daniel de MuratUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France.
Florence TubachSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie Et de Santé Publique, AP-HP, 1901, F-75013, Paris, France.
Pierre HausfaterEmergency Department, APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, GRC-14 BIOSFAST, CIMI, UMR 1135, Sorbonne Université, Paris, France.
Tabassome SimonService de Pharmacologie, Plateforme de Recherche Clinique URC-CRC-CRB de L'Est Parisien, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Antoine, Sorbonne Université, Paris, France.
Guy GorochovCentre d'Immunologie Et Des Maladies Infectieuses (CIMI), Department of Immunology, Sorbonne Université, Inserm, Hôpital Pitié Salpêtrière, Groupe Hospitalo-Universitaire Assistance Publique - Hôpitaux de Paris, Paris, France.
Valérie PourcherDepartment of Infectious Diseases, Hôpital Pitié Salpêtrière, Groupe Hospitalo-Universitaire Assistance Publique - Hôpitaux de Paris, Sorbonne Université, Paris, France.
Alexandra BeurtonService de Médecine Intensive Réanimation EOLE - Département R3S - Sorbonne, Université - Hôpital Universitaire Pitié - Salpêtrière - Assistance Publique Hôpitaux de Paris - 83 Boulevard de L'Hôpital, 75013, Paris, France.
Hélène GouletEmergency Department, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France.
Philippe ManivetINSERM UMR 1141 "NeuroDiderot", Université Paris Cité, FHU I2-D2, Paris, France.
Jérôme BertheratUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France.
Guillaume AssiéUniversité Paris Cité, CNRS UMR8104, INSERM U1016, Institut Cochin, F-75014, Paris, France. guillaume.assie@aphp.fr.
COVIDeF group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is associated with heterogeneous outcome. Early identification of a severe progression of the disease is essential to properly manage the patients and improve their outcome. Biomarkers reflecting an increased inflammatory response, as well as individual features including advanced age, male gender, and pre-existing comorbidities, are risk factors of severe COVID-19. Yet, these features show limited accuracy for outcome prediction. The aim was to evaluate the prognostic value of whole blood transcriptome at an early stage of the disease. Blood transcriptome of patients with mild pneumonia was profiled. Patients with subsequent severe COVID-19 were compared to those with favourable outcome, and a molecular predictor based on gene expression was built. Unsupervised classification discriminated patients who would later develop a COVID-19-related severe pneumonia. The corresponding gene expression signature reflected the immune response to the viral infection dominated by a prominent type I interferon, with IFI27 among the most over-expressed genes. A 48-genes transcriptome signature predicting the risk of severe COVID-19 was built on a training cohort, then validated on an external independent cohort, showing an accuracy of 81% for predicting severe outcome. These results identify an early transcriptome signature of severe COVID-19 pneumonia, with a possible relevance to improve COVID-19 patient management.

Indexed as

COVID-19SARS-CoV-2TranscriptomeAdultAgedBiomarkersCohort StudiesFemaleGene Expression ProfilingHumansMaleMembrane ProteinsMiddle AgedPrognosisSeverity of Illness IndexBiomarkersIFI27 protein, humanMembrane ProteinsBlood transcriptomeCOVID-19PredictionSevere pneumonia

Identifiers

PMID38772950
PMCPMC11108918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.